Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

NexPoint Real Estate Finance, Inc. (the "Company") announced today the final income allocations of the Company's 2024 dividend distributions on its common stock, Series A Preferred Stock and Series B ...

The controversy stems from PhRMA's statement claiming the ad misrepresents the safety and efficacy of Hims and Hers' products and may violate marketing rules. Additionally, two US senators expressed ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Online sellers of knockoff GLP-1 drugs have seized on shortages as an opportunity to advertise a more steady, lower-cost supply of the products compared to branded versions. One such company, Hims & ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded ...

The Super Bowl debut by digital healthcare company Hims & Hers is now listed on the injury report as questionable, following ...